NYSE:IQVIqvia Stock Price, Forecast & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IQV stock has increased by 13.8% and is now trading at $142.68. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Iqvia.

Iqvia will be holding an earnings conference call on Wednesday, July 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Iqvia Holdings Inc (NYSE:IQV) issued its earnings results on Tuesday, April, 28th. The medical research company reported $1.50 EPS for the quarter, topping analysts' consensus estimates of $1.48 by $0.02. The medical research company earned $2.75 billion during the quarter, compared to the consensus estimate of $2.74 billion. Iqvia had a net margin of 1.93% and a return on equity of 18.48%. The business's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm earned $1.53 earnings per share. View Iqvia's earnings history.

Iqvia issued an update on its second quarter earnings guidance on Tuesday, April, 28th. The company provided earnings per share guidance of $1.00 to $1.09 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.15. The company issued revenue guidance of $2.365 billion to $2.440 billion, compared to the consensus revenue estimate of $2.47 billion.

17 analysts have issued twelve-month target prices for Iqvia's stock. Their forecasts range from $110.00 to $195.00. On average, they expect Iqvia's stock price to reach $153.65 in the next year. This suggests a possible upside of 7.7% from the stock's current price. View analysts' price targets for Iqvia.

News articles about IQV stock have trended somewhat positive on Sunday, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a daily sentiment score of 1.3 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Iqvia.

Iqvia saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 2,600,000 shares, a decline of 5.8% from the June 15th total of 2,760,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the short-interest ratio is currently 1.7 days. Currently, 1.4% of the company's stock are short sold. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Pieris Pharmaceuticals (PIRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL) and Accenture (ACN).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.17%), DNB Asset Management AS (0.06%), Whittier Trust Co. (0.03%), Gradient Investments LLC (0.02%), State of Alaska Department of Revenue (0.02%) and UNIVEST FINANCIAL Corp (0.01%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View institutional ownership trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Chesley Taft & Associates LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, and Michael R Mcdonnell. View insider buying and selling activity for Iqvia.

IQV stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Gradient Investments LLC, Whittier Trust Co., DNB Asset Management AS, UNIVEST FINANCIAL Corp, Fulton Bank N. A., First American Trust FSB, and Whittier Trust Co. of Nevada Inc.. View insider buying and selling activity for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $142.68.

Iqvia has a market capitalization of $27.25 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

The official website for Iqvia is www.iqvia.com.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]